Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (January 2023)
31 slides from Sonoma Pharmaceuticals's investor presentation, Jan 6, 2023
Slide 1: Sonoma Pharmaceuticals, Inc. January 2023
Sonoma Pharmaceuticals, Inc. January 202 3
Slide 2: Legal Disclaimers
Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness
Slide 3: Legal Disclaimers: Non-GAAP Measures and Trademarks
NON - GAAP FINANCIAL MEASURES Non - GAAP income (loss) from operations minus non - cash expenses (EBITDAS) is a non - GAAP financial measure. The Company defines operating income (loss) minus non - cash expenses as GAAP reported operating income (loss) minus operating depreciation and amorti zation,
Slide 4: Sonoma Pharmaceuticals global healthcare leader in stabilized HOCl
Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid ( HOCl ) products for a wide range of applications, including dermatology, wound care, eye care, nasal care, oral care, animal health and non - toxic disinfectants. Sonoma’s products are cl
Slide 5: Investor Highlights
Investor Highlights Diverse global healthcare leader • Focused on billion - dollar markets in Rx and OTC dermatology, wound care, eye, oral and nasal care, animal health and non - toxic disinfectants treating common injuries, infections and irritations that virtually everyone experiences • Over 20 y
Slide 6: Growth plan: expand Rx and OTC reach
• Expand Rx and OTC reach in U.S. in the dermatology, wound care, eye, oral and nasal care, animal care and non - toxic disinfectant s markets via direct - to - consumer sales and distribution partnerships • Fully commercialize robust pipeline of new products via direct - to - consumer sales or dist
Slide 7: Recent product launches and partnerships
• In January 2023, Sonoma launched two new products, Reliefacyn® Plus Itch - Burn - Rash - Pain Relief Hydrogel and Rejuvacyn ® Plus Skin Repair Cooling Mist, expanding its line of office dispense products exclusively for dermatologists and medical spas. • Sonoma launched two new over - the - counte
Slide 8: Market Opportunities
• The global natural skin care products market size was valued at $6.7 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 6.6% from 2022 to 2030. 1 • The global medical spa market size was valued at $16.4 billion in 2022 and is expected to expand at a compound annua
Slide 9: Growth Strategy
• Increase sales of dermatology products through the direct dispense model that generates Sonoma’s highest margins by leveraging Sonoma’s existing relationships with dermatologists and skin care professionals • Increase direct - to - consumer marketing in niche markets to generate greater overall ma
Slide 10: Sonoma's Microcyn Technology
Sonoma’s Microcyn Technology Stable triple - action topical technology • A powerful anti - microbial – reduces microbial load, including destruction of biofilms • Anti - inflammatory agent – reduces itch and pain • Anti - pruritic activity • Tissue healing (increased blood/oxygen flow to wound) Unpa
Slide 11: What is Hypochlorous Acid?
What is Hypochlorous Acid? During the activation of neutrophils, respiratory bursts generate hydrogen peroxide (H 2 O 2 ) and the activated granule enzyme myeloperoxidase converts H 2 O 2 to hypochlorous acid (HOCl) • Hypochlorous acid (HOCl) is produced by neutrophils in the body as part of its def
Slide 12: Microcyn Technology microbial load reduction & infection control
Microcyn Technology microbial load reduction & infection control MRSA - Staphylococcus aureus 99.999 VRE - Enterococcus faecalis 99.999 Staphylococcus aureus 99.999 Escherichia coli 99.997 Acinetobacter baumannii 99.999 Bacteroides fragilis 99.999 Candida albicans 99.999 Enterobacter aerogene 99.999
Slide 13: Research and Development
Research and Development Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn ® technology can be found on our website at https://sonomapharma.com/literature/ . Here is a sample: • Dermodacyn ® Disinfecting solution study on viability of SA
Slide 14: FDA-cleared products and competitive strengths
• FDA - cleared products targeting: • Atopic dermatitis, dermal lesions (acne), scar management, symptoms of eczema, pain and itch relief and other dermatological conditions • Eye care, including eye - lash hygiene • Medspa and beauty markets for skin care and repair • Acute and chronic wound care •
Slide 15: U.S. Product Offerings
U.S. Product Offerings Ocucyn Eyelid & Eyelash Cleanser Microcyn Rx Skin & Wound Care Regenacyn Advanced Scar Gel Epicyn Antimicrobial Facial Cleanser Acuicyn Antimicrobial Eyelid & Eyelash Hygiene Levicyn Antimicrobial Dermal Spray Celacyn Scar Management Gel Rejuvacyn Skin Repair Reliefacyn Itch,
Slide 16: Animal Health Care
Animal Health Care MicrocynAH ® family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • Sold in national pet - store retail chains a
Slide 17: Robust International Distribution Network
Robust International Distribution Network • Steadily growing existing partner base with broad indications • ISO/FDA registered/CE/EN/MOH/TGA registrations for state - of - the - art Mexico manufacturing facility • Ship to 55 countries globally • 40+ partners in dermatology, eye, wound, oral and nasa
Slide 18: Cutting Edge Manufacturing
• ISO 9001, ISO 13485 and cGMP certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and many other national listing/approvals • Shipping to 55 countries • Highly trained staff • Flexibility In Use Of Indications, SKUs, Packaging & Labeling Cutting Edge Manufacturing
Slide 19: Guadalajara plant
Located in Guadalajara, Mexico Laboratory Packaging Area Labeling Boxing Ready for shipment Warehouse Air Systems Product Water Treatment System Materials Testing Laboratory Guadalajara plant
Slide 20: EU Products
Epicyn ® Dermatology Gramaderm ® Dermatology Pediacyn ® Dermatology Mucoclyns ® Decontamination solution Microdacyn60 ® Oral Care Blocked nose or sinuses Sinudox ® Nasal care Blepharitis treatment Ocudox ® Eye lid solution Exposure to germs and pathogens Mouth and throat infections Keloid or hypertr
Slide 21: Latin America products
Latin America Celacyn Scar Management Gel Gramacyn Kit for Acne Skin Microdacyn Wound Care
Slide 22: Asia products
Asia Singapore, Malaysia, Thailand, Indonesia WoundCare South Korea BioDerm & Biodacyn60 Wound Care Hong K ong Microdacyn60 Oral Care China Microcyn The Philippines M icrodacyn MicrocynAH
Slide 23: Middle East products
Middle East Microsafe Disinfectant & Sanitizer Microsafe Disinfectant & Sanitizer Microsafe Face Cool, Anti - Microbial, Baby Cool, Foot Cool, Lady Cool Microdacyn Wound Care
Slide 24: Australia and New Zealand products
Australia and New Zealand Epicyn Treat Scars Right from the Start Microdox Super - Oxidised Solution Bladder & Catheter Rinse Microdacyn Surgical Irrigation and Wound Treatment
Slide 25: Our Global Brands & Partners
Growing our own brands and/or partner brands Our Global Brands & Partners
Slide 26: Key Financial Metrics
Key Financial Metrics * dollars in thousands Six Months Ended Six Months Ended Sept. 30, 2022 * (unaudited) Sept. 30, 2021* (unaudited) Total Revenues $7,314 $7,428 Gross Profit $2,782 $2,694 Operating Expenses $4,368 $4,563 Net Income (Loss) $(1,904) $(1,198) EBITDAS loss $(1,200) $(1,655) Cash & C
Slide 27: Balance Sheet Highlights
Balance Sheet Highlights September 30, 2022 March 31, 2022 ASSETS (unaudited) Current assets: Cash and cash equivalents $ 3,3 5 1 $ 7,396 Accounts receivable, net 2,487 2,407 Inventories, net 3,025 2,663 Other current assets 3,530 3,964 Total current assets 12,393 16,430 Other assets 2,569 2,415 Tot
Slide 28: Income Statement, September 30, 2022
Income Statement, September 30, 2022 Six Months Ended September 30, 2022 2021 Revenues $ 7,314 $ 7,428 Cost of revenues 4,532 4,734 Gross profit 2,782 2,694 Operating expenses Research and development 6 95 Selling, general and administrative 4,362 4,468 Total operating expenses 4,368 4,563 Loss from
Slide 29: Statement of Cash Flows, Sept. 30, 2022
Statement of Cash Flows, Sept. 30, 2022 Six Months Ended September 30, 2022 2021 Net cash (used in) provided by operating activities $ (3,363) $ (2,527) Net cash (used in) provided by investing activities (210) (38) Net cash (used in) provided by financing activities (565) 6,711 Effect of exchange r
Slide 30: Revenue Metrics
Revenue Metrics Revenues by revenue source: Six Months Ended September 30, 2022 2021 Human Care $ 4,615 $ 5,186 Animal Care 1,523 1,937 Service and Royalty 1,176 305 $ 7,314 $ 7,428 Revenue by geographic region: Six Months Ended September 30, 2022 2021 United States $ 1,842 2,939 Europe 2,012 1,688
Slide 31: Thank You
THANK YOU Sonoma Pharmaceuticals Inc. 5445 Conestoga Court , Suite 150 Boulder , CO 80301 United States of America Phone: 1 - (800) 759.9305 Email: busdev@sonomapharma.com Website: www.sonomapharma.com NASDAQ: SNOA
Sonoma Pharmaceuticals — Investor Presentation (January 2023) on 6ix